The dysregulated Type 2 immune response drives AD
Type 2 inflammation, due to increased signalling of IL-4 and IL-13, contributes to the clinical disease features of AD4–6
Dysregulation of the Type 2 immune response5,7
Leads to increased signalling and production of IL-4 and IL-135
Which drives and perpetuates Type 2 inflammation5
Resulting in the clinical disease features of AD:4,6
• Skin barrier dysfunction
• Skin lesions
• Increased susceptibility to skin infections
Selectively targeting a single signalling receptor, the IL-4Rα, thereby inhibiting IL-4 and IL-13 signalling, can help to reduce the persistent underlying Type 2 inflammation in AD8
- DUPIXENT Summary of Product Characteristics. September 2021.
- Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
- Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
- Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
- Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
- Biedermann T, et al. Front Immunol. 2015;6:353.
- Artis D & Spits H. Nature. 2015;517:293–301.
- Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155– 172.
AD, atopic dermatitis; IL, interleukin; IL-4Rα, interleukin 4 receptor alpha; ILC, innate lymphoid cells; Th, T-helper cells.
MAT-IE-2101040(v4.0) | Date of preparation: February 2022